Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Aclarion, Inc. ( (ACON) ) has shared an announcement.
On March 19, 2026, Aclarion’s board unanimously adopted a limited-duration stockholder rights plan, effective immediately and expiring March 18, 2027, and declared a dividend of one preferred stock purchase right for each share of common stock and each rights-eligible warrant outstanding as of March 30, 2026. Each right will initially trade with the underlying securities and become exercisable if any shareholder or group acquires 10% or more of the common stock without board approval, allowing other holders to buy securities at a substantial discount or receive shares in an acquirer in a change-of-control transaction.
The plan, which the company said was not adopted in response to any specific takeover proposal and applies equally to all investors, is structured to discourage opportunistic attempts to gain control without paying a premium, while preserving the board’s ability to consider strategic offers it deems fair. By putting a one-year, non–dead-hand rights plan in place with redemption and exchange features, Aclarion aims to protect its shareholder base, secure time for board deliberation in the event of unsolicited approaches and align itself with governance practices seen at other small publicly traded issuers.
The most recent analyst rating on (ACON) stock is a Buy with a $23.00 price target. To see the full list of analyst forecasts on Aclarion, Inc. stock, see the ACON Stock Forecast page.
More about Aclarion, Inc.
Aclarion, Inc. is a healthcare technology company that leverages Magnetic Resonance Spectroscopy, proprietary signal processing, biomarkers and augmented intelligence algorithms to optimize clinical treatments. The company initially targets the chronic low back pain market with Nociscan, a SaaS platform designed to noninvasively help physicians distinguish between painful and nonpainful lumbar discs.
Average Trading Volume: 896,577
Technical Sentiment Signal: Sell
Current Market Cap: $3.5M
Learn more about ACON stock on TipRanks’ Stock Analysis page.